Kaiku Health secures €4.4 million series A financing from Prodeko, Tesi and Debiopharm to accelerate its digital therapeutics pipeline

Finland Switzerland 05 April 2018

Kaiku Health, a Helsinki, Finland-based company providing a digital health platform, announced securing  a €4.4M ($5.4M) in an investment funding round.

The backing was led by by Debiopharm Innovation Fund SA, Tesi and Prodeko Ventures Oy, and included existing investors Reaktor Ventures Oy, Metsola Ventures Oy, and Athensmed Oy.

The money will be used to support the company's international expansion and further develop its digital therapeutics pipeline. Together with its partners, Kaiku Health will conduct several clinical trials validating the digital therapeutics offering.

Kaiku Health, founded as NetMedi in 2012 by Henri Virtanen, Joel Lehikoinen, Kaarlo Haikonen, and Lauri Sippola (CEO), offers intelligent patient monitoring software for healthcare providers. Structured capture and analysis of patient-reported data enables clinicians to evaluate the effectiveness of therapies and to detect and treat health problems early. Kaiku Health platform is used in routine care by over 30 clinics in Switzerland, Germany, Italy, Sweden, and Finland, and has been used by 64,000 patients as of March 2018.

Prior to this deal, Kaiku raised a little more than $1M in three capital rounds in 2013, 2015 and 2016.

Total investments received (USD): 6.6M